Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DIAB MFREJ ALMHANA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1619053477
CMS profile
164255
Location
AVON LAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$72,053.39

338 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DIAB MFREJ ALMHANA

NPI 1619053477 · CMS profile ID 164255

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

AVON LAKE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

338 matching records · $72,053.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 338 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 338.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $34.0809/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133894631 CMS
Otsuka America Pharmaceutical, Inc. $15.7108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118851600 CMS
Alkermes, Inc. $13.4208/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120456789 CMS
Corium, LLC $6.6708/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100148333 CMS
Supernus Pharmaceuticals, Inc. $3.9108/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860897 CMS
Supernus Pharmaceuticals, Inc. $12.4108/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860905 CMS
Supernus Pharmaceuticals, Inc. $73.6508/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860923 CMS
Supernus Pharmaceuticals, Inc. $95.8008/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860925 CMS
Supernus Pharmaceuticals, Inc. $214.3308/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860939 CMS
Supernus Pharmaceuticals, Inc. $2,000.0008/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860951 CMS
Supernus Pharmaceuticals, Inc. $2,000.0008/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860953 CMS
Bausch Health US, LLC $24.4208/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148018748 CMS
Supernus Pharmaceuticals, Inc. $20.3008/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860913 CMS
Supernus Pharmaceuticals, Inc. $25.4908/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860919 CMS
Supernus Pharmaceuticals, Inc. $50.0008/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860921 CMS
Supernus Pharmaceuticals, Inc. $214.3108/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860935 CMS
Supernus Pharmaceuticals, Inc. $214.3108/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860937 CMS
Supernus Pharmaceuticals, Inc. $2,000.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860947 CMS
Supernus Pharmaceuticals, Inc. $2,000.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860949 CMS
Supernus Pharmaceuticals, Inc. $223.4308/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860955 CMS
Supernus Pharmaceuticals, Inc. $491.3808/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860957 CMS
Supernus Pharmaceuticals, Inc. $1,000.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860961 CMS
ABBVIE INC. $4.2208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210237 CMS
Teva Pharmaceuticals USA, Inc. $35.3308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151668901 CMS
Corium, LLC $21.5408/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100182188 CMS
ABBVIE INC. $4.2908/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210235 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,160.0008/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143183114 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.8308/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143183118 CMS
Supernus Pharmaceuticals, Inc. $24.2408/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860917 CMS
Alkermes, Inc. $14.0608/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120456787 CMS
Lundbeck LLC $6.5908/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145890911 CMS
Lundbeck LLC $3.7408/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145890913 CMS
Supernus Pharmaceuticals, Inc. $147.9908/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860933 CMS
ABBVIE INC. $6.3708/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210233 CMS
IRONSHORE PHARMACEUTICALS INC. $15.6808/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146298376 CMS
Supernus Pharmaceuticals, Inc. $0.0108/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860891 CMS
Supernus Pharmaceuticals, Inc. $0.0108/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860893 CMS
Supernus Pharmaceuticals, Inc. $17.3008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860911 CMS
Supernus Pharmaceuticals, Inc. $147.9808/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860927 CMS
Supernus Pharmaceuticals, Inc. $147.9908/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860929 CMS
Supernus Pharmaceuticals, Inc. $147.9908/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147860931 CMS
ABBVIE INC. $4.4908/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210231 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.3308/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137468877 CMS
Tris Pharma Inc $14.2908/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147234379 CMS
ABBVIE INC. $3.8807/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210229 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $13.9307/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143183110 CMS
Alkermes, Inc. $16.8607/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120456785 CMS
ABBVIE INC. $13.4507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103210227 CMS
Neos Therapeutics, LP $14.3307/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082672051 CMS
Axsome Therapeutics, Inc. $25.5607/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148277158 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,656.90 187
PY2020 $19,369.72 143
PY2021 $26,554.52 218
PY2022 $41,770.93 256
PY2023 $83,932.01 299
PY2024 $72,053.39 338
PY2025 $167,781.51 459

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,312.88 9
PY2025 Principal investigator $427,508.07 81
PY2024 Principal investigator $481,234.52 54
PY2023 Principal investigator $476,495.70 64
PY2022 Principal investigator $76,290.31 27
PY2021 Principal investigator $352,859.78 33
PY2020 Recipient $1,501.41 8
PY2020 Principal investigator $226,275.36 25
PY2019 Recipient $957.49 6
PY2019 Principal investigator $195,107.96 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,592.56 12/31/2025 Non-covered Recipient Entity
HAIDAR ALMHANA AND NIEDING LLC
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202533055
Principal investigator 1 ABBVIE INC. $3,132.24 12/31/2025 Non-covered Recipient Entity
HAIDAR ALMHANA AND NIEDING LLC
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202533057
Principal investigator 1 ABBVIE INC. $1,558.04 12/31/2025 Non-covered Recipient Entity
HAIDAR ALMHANA AND NIEDING LLC
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202533059
Principal investigator 1 ABBVIE INC. $2,402.52 12/31/2025 Non-covered Recipient Entity
HAIDAR ALMHANA AND NIEDING LLC
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202533061
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,040.62 12/22/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242369433
Recipient ABBVIE INC. $707.79 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397110
Recipient ABBVIE INC. $60.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397114
Recipient ABBVIE INC. $24.99 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397118
Recipient ABBVIE INC. $70.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397122
Recipient ABBVIE INC. $84.55 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397125
Recipient ABBVIE INC. $235.25 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397095
Recipient ABBVIE INC. $29.40 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397098
Recipient ABBVIE INC. $50.90 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397103
Recipient ABBVIE INC. $50.00 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202397106
Principal investigator 1 ABBVIE INC. $21,192.35 12/04/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202528352
Principal investigator 1 ABBVIE INC. $11,709.30 12/04/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202528370
Principal investigator 1 ABBVIE INC. $7,226.75 12/04/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202528372
Principal investigator 1 Janssen Research & Development, LLC $363.00 11/17/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332193
Principal investigator 1 ABBVIE INC. $4,961.95 11/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202521593
Principal investigator 1 ABBVIE INC. $11,356.20 11/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202521607
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 11/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332185
Principal investigator 1 ABBVIE INC. $9,024.75 10/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202515829
Principal investigator 1 ABBVIE INC. $14,500.00 10/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive Disorder No dispute reported 06/30/2026 1202515831
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,608.00 10/02/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242360038
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 09/24/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242359558
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $400.00 09/22/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242359216
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,774.89 08/18/2025 Non-covered Recipient Entity
QUEST THERAPEUTICS OF AVON LAKE
ACP-103-070 No dispute reported 06/30/2026 1245935517
Principal investigator 1 ABBVIE INC. $3,600.00 07/28/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202500170
Principal investigator 1 ABBVIE INC. $1,650.00 07/24/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202499556
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,546.00 07/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242353819
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,079.00 07/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242353821
Principal investigator 1 ABBVIE INC. $2,385.45 07/02/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202495027
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,134.00 06/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242351540
Principal investigator 1 ABBVIE INC. $580.00 06/10/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202490741
Principal investigator 1 ABBVIE INC. $33,822.75 06/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202488943
Principal investigator 1 ABBVIE INC. $1,425.60 06/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202488945
Principal investigator 1 ABBVIE INC. $9,472.00 05/22/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202485769
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $754.00 05/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242348242
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,220.00 05/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242348284
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,846.00 05/19/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-505 No dispute reported 06/30/2026 1242347576
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,106.00 05/19/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-505 No dispute reported 06/30/2026 1242347578
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,100.00 05/19/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-505 No dispute reported 06/30/2026 1242347580
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,200.00 05/12/2025 Non-covered Recipient Entity
QUEST THERAPEUTICS OF AVON LAKE
ACP-103-070 No dispute reported 06/30/2026 1245934213
Principal investigator 1 ACADIA Pharmaceuticals Inc $125.78 05/12/2025 Non-covered Recipient Entity
QUEST THERAPEUTICS OF AVON LAKE
ACP-103-069 No dispute reported 06/30/2026 1245934215
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $800.00 05/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242347338
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 05/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242347340
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $850.00 05/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242347342
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,000.00 05/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242347344
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 05/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242347346
Principal investigator 1 ABBVIE INC. $30,152.10 05/07/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202482581
Principal investigator 1 ABBVIE INC. $2,000.00 05/07/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202482583
Principal investigator 1 ABBVIE INC. $14,500.00 05/07/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202482585
Principal investigator 1 ABBVIE INC. $4,295.25 05/06/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202481317
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,157.00 04/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242343971
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,054.00 04/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242343973
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $95.00 04/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242343975
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $87.00 04/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242343977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $40.00 04/23/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242343979
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,775.72 04/10/2025 Non-covered Recipient Entity
QUEST THERAPEUTICS OF AVON LAKE
ACP-103-069 No dispute reported 06/30/2026 1245934045
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $178.00 04/09/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242340834
Principal investigator 1 ABBVIE INC. $3,565.00 04/08/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202474977
Principal investigator 1 ABBVIE INC. $1,849.50 04/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202471875
Principal investigator 1 ABBVIE INC. $27,717.30 04/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202472233
Principal investigator 1 ABBVIE INC. $14,500.00 04/03/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202472236
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,220.00 04/02/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242339071
Principal investigator 1 Janssen Research & Development, LLC $22,050.00 03/24/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332199
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,862.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338625
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,306.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338627
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,128.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338629
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,128.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338631
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,794.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338633
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,128.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338635
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,128.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338639
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $74.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338641
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $40.00 03/21/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-602 No dispute reported 06/30/2026 1242338643
Principal investigator 1 ABBVIE INC. $9,897.00 03/07/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202461796
Principal investigator 1 ABBVIE INC. $3,275.10 03/06/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202458584
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,134.00 02/25/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242333024
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,608.00 02/25/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242333026
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,338.00 02/25/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242333238
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,617.00 02/25/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242333240
Principal investigator 1 ABBVIE INC. $338.85 02/06/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202449120
Principal investigator 1 ABBVIE INC. $8,122.50 02/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202445539
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,499.00 02/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242329977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,608.00 02/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242329985
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,940.00 02/05/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-321 No dispute reported 06/30/2026 1242329987
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,709.00 01/13/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242328639
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,044.00 01/13/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242328641
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,044.00 01/13/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242328643
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,970.00 01/13/2025 Non-covered Recipient Entity
HAIDAR ALMHANA NIEDING LLC
ITI-007-421 No dispute reported 06/30/2026 1242328645